🔍

ORCHASP - Orchasp Ltd

📊 NSE: ORCHASP 🏢 Computers - Software - Medium / Small 📅 Last Updated: 12/14/2025 10:43

📢 Recent Corporate Announcements

Orchasp Appoints Ravi Prasad Muthyam as Independent Director for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 06 Mar 2026, 05:30 PM

Orchasp Limited has appointed Mr. Ravi Prasad Muthyam as an Additional Independent Director for a five-year term effective March 6, 2026, subject to shareholder approval. Mr. Muthyam brings over 26 years of experience in banking and financial services, including 15 years in corporate fundraising and financial advisory. Following this appointment, the company has reconstituted its Board Committees, with Mr. Muthyam taking over as Chairperson of the Audit Committee. This move aims to strengthen the company's financial oversight and governance framework.

Appointment of Mr. Ravi Prasad Muthyam as Independent Director for a 5-year term ending March 5, 2031.
Mr. Muthyam has over 26 years of experience in banking, financial services, and corporate fundraising.
He has been appointed as the Chairperson of the Audit Committee and a member of the Stakeholders Relationship Committee.
The Board has reconstituted four major committees: Audit, Nomination & Remuneration, Stakeholders Relationship, and CSR.
The appointment is in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 This is a routine governance update; investors should monitor if the new director's financial expertise leads to improved internal controls or better fundraising capabilities. No immediate trading action is required based on this announcement.

Orchasp Appoints Ravi Prasad Muthyam as Independent Director; Reconstitutes Board Committees

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 06 Mar 2026, 05:21 PM

Orchasp Limited has announced the appointment of Mr. Ravi Prasad Muthyam as an Additional Independent Director for a five-year term effective March 06, 2026. Mr. Muthyam brings over 26 years of experience in the banking and financial services sector, including 15 years in corporate fundraising and financial advisory. Following this appointment, the company has reconstituted its Audit, Nomination & Remuneration, Stakeholders Relationship, and CSR committees. Notably, Mr. Muthyam will serve as the Chairperson of the Audit Committee, enhancing the board's financial oversight capabilities.

Appointment of Mr. Ravi Prasad Muthyam as Independent Director for a 5-year term ending March 05, 2031.
Mr. Muthyam has 26+ years of experience in banking and financial services, including 15 years in fundraising.
Reconstitution of four key board committees: Audit, Nomination & Remuneration, Stakeholders Relationship, and CSR.
Mr. Muthyam will serve as the Chairperson of the Audit Committee effective March 06, 2026.

💡 This is a routine governance update; investors should monitor if the new director's fundraising expertise leads to future capital infusion or improved financial strategy. No immediate action is required based on this announcement.

Orchasp's INDUSAYUSH Health Platform Approved for Apple App Store

🟢 POSITIVE ⭐ 5/10

EXPANSION 📅 24 Feb 2026, 07:46 PM

Orchasp Limited has announced that its electronic health records (EHR) platform, INDUSAYUSH, was officially admitted to the Apple App Store on February 24, 2026. This milestone allows the company to distribute its digital health solution to a global iOS user base, enhancing its market reach. The approval follows the platform's development as a key digital asset for the company. Investors should note this as a positive step in the company's product scaling and digital health strategy.

INDUSAYUSH electronic health records platform admitted to Apple App Store on February 24, 2026
The app is now available for global distribution to iOS users via the App Store
Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
The move enables the company to leverage Apple's ecosystem for user engagement and monetization

💡 Investors should monitor the adoption rates and user feedback of the INDUSAYUSH app to gauge its potential impact on future revenue. Watch for updates on the platform's monetization strategy in upcoming quarterly earnings calls.

Orchasp Ltd Approves Q3 Results with Qualified Audit Opinion and Major Board Reconstitution

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 10 Feb 2026, 04:00 PM

Orchasp Limited has approved its unaudited financial results for the quarter ended December 31, 2025, which notably received a qualified opinion from statutory auditors. The company is undergoing a significant board transition with the appointment of two new directors, including the sister of the current MD & CFO as a Non-Executive Director. Simultaneously, three Independent Directors are scheduled to exit the board between February and March 2026 following the completion of their tenures. This has led to a full reconstitution of the Audit, Nomination, and Stakeholders Relationship committees.

Statutory auditors JMT & Associates issued a qualified opinion on the Q3 FY2025-26 financial results.
Mr. Srinivasu Sunkara appointed as Independent Director for a 5-year term effective February 10, 2026.
Ms. Sirisha Pattapurathi, sister of MD & CFO P. Chandra Sekhar, appointed as Non-Executive Non-Independent Director.
Three Independent Directors (Ms. Ponnari Gottipati, Mr. Bade Srinivasa Reddy, and Mr. Sai Roopkumar Vegunta) to cease office by March 6, 2026.
Board committees including Audit and Stakeholders Relationship reconstituted effective February 10, 2026.

💡 Investors should exercise caution and specifically review the 'qualified opinion' in the financial statements to understand the auditor's concerns. The simultaneous exit of three independent directors and the appointment of a promoter-related director warrant close monitoring of corporate governance standards.

Orchasp Ltd Appoints New Directors; Q3 FY26 Results Receive Qualified Auditor Opinion

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 10 Feb 2026, 03:40 PM

Orchasp Limited has announced a significant board reshuffle, appointing Mr. Srinivasu Sunkara as an Independent Director for a five-year term and Ms. Sirisha Pattapurathi as a Non-Executive Director. These appointments coincide with the upcoming departure of three Independent Directors between February and March 2026. Notably, the company's Q3 FY26 financial results were approved but received a qualified opinion from the statutory auditors, JMT & Associates. Investors should note that Ms. Pattapurathi is the sister of the current Managing Director and CFO.

Appointment of Mr. Srinivasu Sunkara as Independent Director for a 5-year term ending February 2031.
Ms. Sirisha Pattapurathi appointed as Non-Executive Director; she is the sister of the MD & CFO.
Three Independent Directors (Ms. Ponnari Gottipati, Mr. Bade Reddy, and Mr. Sai Vegunta) to exit by March 6, 2026.
Statutory auditors issued a qualified opinion on the unaudited financial results for the quarter and nine months ended December 31, 2025.
Board committees, including Audit and Nomination, were reconstituted effective February 10, 2026.

💡 Investors should carefully review the specific reasons behind the auditor's qualified opinion in the Q3 results to assess financial transparency risks. Monitor how the significant turnover in independent directors affects the company's corporate governance standards.

Orchasp Ltd Q3 FY26 Results Approved; Board Reconstituted Amid Auditor Qualification

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 10 Feb 2026, 03:26 PM

Orchasp Limited has approved its Q3 FY26 financial results, which notably received a qualified opinion from statutory auditors JMT & Associates. The company is undergoing a major board transition with the appointment of Mr. Srinivasu Sunkara as an Independent Director and Ms. Sirisha Pattapurathi as a Non-Executive Director. This follows the upcoming cessation of three independent directors—Ms. Ponnari Gottipati, Mr. Bade Srinivasa Reddy, and Mr. Sai Roopkumar Vegunta—by March 2026. Consequently, the Audit and other board committees have been reconstituted to align with the new leadership structure.

Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Statutory auditors issued a qualified opinion on the financial statements, indicating potential accounting concerns.
Appointed Mr. Srinivasu Sunkara as Independent Director for a five-year term ending February 2031.
Ms. Sirisha Pattapurathi, sister of the MD & CFO, appointed as a Non-Executive Non-Independent Director.
Three Independent Directors to step down by March 2026 upon completion of their respective terms.

💡 Investors should exercise caution and investigate the specific nature of the auditor's qualified opinion. The significant turnover in independent directors and the appointment of a promoter relative to the board suggest a need for heightened monitoring of corporate governance.

Orchasp Limited Achieves 100% Compliance in SEBI Structured Digital Database for Q3 FY26

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 09 Jan 2026, 09:31 PM

Orchasp Limited has successfully submitted its compliance certificate for the Structured Digital Database (SDD) for the quarter ended December 31, 2025. The certification, provided by a Practicing Company Secretary, confirms that the company is adhering to SEBI (Prohibition of Insider Trading) Regulations. During the quarter, the company identified and recorded 1 specific event involving Unpublished Price Sensitive Information (UPSI). No non-compliances were reported, reflecting a robust internal system for monitoring insider trading risks.

Confirmed 100% compliance with SEBI (Prohibition of Insider Trading) Regulations for the quarter.
Successfully captured 1 required UPSI event in the internal Structured Digital Database.
The database is verified as non-tamperable with an audit trail capability of 8 years.
Zero non-compliances or remedial actions were reported by the verifying Company Secretary.

💡 This is a routine regulatory filing that demonstrates the company's commitment to corporate governance and SEBI compliance. No immediate investment action is required based on this report.

Orchasp Limited Files SEBI Reg 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jan 2026, 05:48 PM

Orchasp Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Aarthi Consultants Pvt Ltd, covers the period from October 1, 2025, to December 31, 2025. It confirms that the company has processed dematerialization requests within the mandated 15-day timeframe. This is a standard procedural filing to ensure the integrity of shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025.
Dematerialization requests were processed and confirmed within 15 days of receipt.
Registrar Aarthi Consultants Pvt Ltd confirmed the mutilation and cancellation of physical certificates.
The filing confirms the substitution of the depository as the registered owner in company records.

💡 This is a routine regulatory filing with no impact on the company's financial performance or valuation. No action is required from investors.

Orchasp's INDUSAYUSH Health Platform Now Live on Google Play Store

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 02 Jan 2026, 12:46 PM

Orchasp Limited has announced the successful admission of its electronic health records (EHR) platform, INDUSAYUSH, on the Google Play Store effective December 31, 2025. This launch represents a key milestone in the company's digital healthcare strategy, providing broader access to its services for Android users. The availability of the app is expected to facilitate user acquisition and enhance the visibility of the company's healthcare technology offerings. Investors should note this as a positive step toward scaling their digital product portfolio.

INDUSAYUSH electronic health records platform admitted to Google Play Store on December 31, 2025
Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
The app is now publicly accessible for download, marking a transition from development to market availability
Move aims to strengthen the company's footprint in the digital health and EHR management sector

💡 Investors should monitor the app's download growth and user reviews to gauge market adoption. It is also important to look for upcoming management commentary regarding the monetization plan for the INDUSAYUSH platform.

Orchasp Limited Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Dec 2025, 04:45 PM

Orchasp Limited has informed the exchanges that its trading window will be closed starting January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is in anticipation of the declaration of the unaudited financial results for the third quarter and nine-month period ending December 31, 2025. The restriction applies to all directors, promoters, and designated persons, including their immediate relatives. The window will remain closed until 48 hours after the financial results are officially announced to the public.

Trading window closure effective from January 1, 2026.
Closure pertains to the unaudited financial results for Q3 and nine months ending December 31, 2025.
Restriction applies to directors, promoters, and designated persons.
Trading window to reopen 48 hours after the declaration of financial results.
Board meeting date for results declaration to be intimated separately.

💡 This is a routine regulatory filing with no direct impact on stock fundamentals; investors should monitor for the upcoming announcement of the Q3 results date.

Orchasp Allots 2.68 Crore Equity Shares at Rs 3.20 to Settle Debt

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 18 Dec 2025, 01:15 PM

Orchasp Limited has approved the allotment of 2,68,75,000 equity shares on a preferential basis at an issue price of Rs 3.20 per share. These shares are being issued to Mrs. P. Rajeswari, the legal heir of the company's former Chairman & CEO, Mr. P.C. Pantulu. The allotment serves to convert outstanding loan amounts into equity, effectively reducing the company's debt liabilities. While this move results in equity dilution, it improves the company's balance sheet by settling debt without cash outflow.

Allotment of 2,68,75,000 equity shares with a face value of Rs 2 each.
Preferential allotment price set at Rs 3.20 per share.
Shares issued to settle outstanding loan amounts of the late ex-Chairman & CEO.
Total transaction value for debt-to-equity conversion is approximately Rs 8.6 crore.
Board has authorized the Managing Director to proceed with listing and trading permissions.

💡 Investors should view the debt reduction as a positive for the company's financial health, though they should be mindful of the resulting equity dilution. Monitor the company's upcoming quarterly results to see the impact of reduced interest burdens.

Orchasp receives in-principle approval for equity share issue

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 12 Dec 2025, 11:04 PM

Orchasp Limited has received in-principle approval from the NSE for issuing equity shares of ₹2 each under preferential terms. The approval is subject to the company fulfilling several conditions, including filing the listing application promptly and complying with regulations from SEBI, RBI, and MCA. The NSE has also advised Orchasp to strengthen internal controls to monitor trading by allottees and ensure compliance with SEBI (ICDR) Regulations. Investors should monitor the company's progress in fulfilling these conditions and ensure compliance with regulatory requirements.

In-principle approval for issue of Equity shares of Rs. 2/- each
Compliance with SEBI (LODR) Regulations, 2015
Compliance with Companies Act, 1956 / Companies Act, 2013
Company advised to strengthen internal controls before allotment of securities

💡 Investors should monitor Orchasp's compliance with the conditions set by NSE and SEBI. Watch for the filing of the listing application and adherence to regulatory guidelines.

Orchasp to Incorporate Wholly-Owned Subsidiary 'Orchasp Inc' in USA

🟡 NEUTRAL ⭐ 6/10

EXPANSION 📅 11 Dec 2025, 08:58 PM

Orchasp Limited is expanding its operations by incorporating a wholly-owned subsidiary named "Orchasp Inc" in the USA. This decision follows a board evaluation that found the cost of reviving the dormant Cybermate Infotek Limited Inc subsidiary to be higher than creating a new one. The new subsidiary will focus on marketing the indusayush health care platform and enabling the mobile app on android and ios playstore. The proposed share capital for Orchasp Inc is 10,000 shares at USD 1 each, totaling USD 10,000.

Incorporating a wholly-owned subsidiary in USA named “Orchasp Inc”.
Proposed share capital of 10,000 Shares of USD 1 each.
Total investment of USD 10,000 in the new subsidiary.

💡 Investors should monitor the performance of the new subsidiary and its impact on Orchasp's overall revenue and profitability. Keep an eye on the adoption and market penetration of the indusayush platform in the US market.

View All ORCHASP Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue from operations for H1 FY26 reached INR 1,528.99 Lakhs, representing a significant growth of 89.6% compared to INR 806.36 Lakhs in H1 FY25. Segment-specific growth percentages are not disclosed as the company reports as a single unit.

Geographic Revenue Split

Not disclosed in available documents, though the company is expanding into the USA with the incorporation of Orchasp Inc in December 2025 to market its healthcare platform.

Profitability Margins

Net profit margin for H1 FY26 stood at 4.9% (INR 74.99 Lakhs profit on INR 1,528.99 Lakhs revenue), a massive recovery from a net loss margin of -174.2% in H1 FY25 (INR 1,404.74 Lakhs loss). This turnaround is primarily due to a 96.2% reduction in 'Other Expenses' from INR 1,547.47 Lakhs to INR 58.66 Lakhs.

EBITDA Margin

Operating profit before working capital changes was INR 99.62 Lakhs (6.5% margin) in H1 FY26, compared to an operating loss of INR 1,393.20 Lakhs in H1 FY25. This indicates a return to core operational viability.

Capital Expenditure

Additions to tangible/intangible assets were minimal at INR 0.12 Lakhs in H1 FY26, down 97.2% from INR 4.32 Lakhs in H1 FY25. The company is focusing on reviving its digital assets rather than heavy physical infrastructure.

Credit Rating & Borrowing

Finance costs were zero in H1 FY26 compared to INR 14.80 Lakhs in H1 FY25, suggesting a reduction in interest-bearing debt. Short-term borrowings increased by INR 20.39 Lakhs during the period.

⚙️ Operational Drivers

Raw Materials

As an IT services firm, the primary 'raw material' is human capital. Employee benefit expenses represent 89.5% of total revenue (INR 1,369.23 Lakhs).

Import Sources

Not applicable for IT services; however, the company is sourcing market access from the USA through its new subsidiary.

Key Suppliers

Not disclosed; the company relies on technology professionals rather than material suppliers.

Capacity Expansion

Current capacity is based on its technology workforce. Planned expansion includes the incorporation of Orchasp Inc (USA) with a share capital of USD 10,000 (INR ~8.3 Lakhs) to scale the 'indusayush' platform globally.

Raw Material Costs

Cost of services/sub-contract costs were INR 1.48 Lakhs in H1 FY26, representing only 0.1% of revenue, down 21.7% from INR 1.89 Lakhs YoY.

Manufacturing Efficiency

Not applicable. Efficiency is measured by the ability to complete fixed-price and fixed-time contracts without cost overruns.

Logistics & Distribution

Distribution is digital via Android and iOS playstores for the 'indusayush' mobile app.

📈 Strategic Growth

Growth Strategy

Growth will be driven by the international launch of the 'indusayush' healthcare platform (www.indusayush.in). The strategy involves incorporating a new US subsidiary, Orchasp Inc, to host mobile apps on global stores and market the platform to a wider audience, bypassing the higher costs of reviving the dormant 'Cybermate Infotek Limited Inc'.

Products & Services

Application development, maintenance, business process outsourcing (BPO) segments, and the 'indusayush' healthcare platform/mobile application.

Brand Portfolio

ORCHASP, indusayush.

New Products/Services

Revival and global marketing of the 'indusayush' healthcare platform via the new US subsidiary.

Market Expansion

Expansion into the USA market through the incorporation of Orchasp Inc in December 2025.

Market Share & Ranking

Not disclosed; identified as a player in the 'mid-segment' technology space.

🌍 External Factors

Industry Trends

The industry is shifting toward performance-linked talent packages and mobile-first healthcare platforms. Orchasp is positioning itself by developing the 'indusayush' app and implementing E-SOPs to stay competitive.

Competitive Landscape

Competes with small and mid-sized companies for Government contracts and large corporations for BPO and application development.

Competitive Moat

The company's moat is built around its proprietary 'indusayush' platform. Sustainability depends on successful global adoption and the ability to maintain a skilled workforce to support the platform.

Macro Economic Sensitivity

Highly sensitive to the general economic environment, which dictates the Risk Management Framework and the availability of long-term IT contracts.

Consumer Behavior

Shift toward mobile-based healthcare services is the primary driver for the 'indusayush' platform development.

Geopolitical Risks

The decision to incorporate in the USA suggests a strategic move to mitigate regional concentration and tap into global tech spending.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to SEBI (Listing Obligations and Disclosure Requirements) Regulations. The company recently faced a disallowance by the BSE regarding the allotment of equity shares pertaining to interest accrued on FCCBs.

Taxation Policy Impact

Current tax for H1 FY26 was INR 26.83 Lakhs. The company monitors tax holidays and subsidies as part of its policy risk management.

Legal Contingencies

The company is dealing with the 'disallowance of allotment of equity shares by the BSE' related to interest on Foreign Currency Convertible Bonds (FCCBs), which resulted in a decrease in share capital compared to the previous year.

⚠️ Risk Analysis

Key Uncertainties

Revenue and expenses are described as 'difficult to predict' and can vary significantly. There is a risk of being unable to recoup investments made in software products like 'indusayush'.

Geographic Concentration Risk

Currently concentrated in India (Hyderabad/Secunderabad), but actively diversifying to the USA.

Third Party Dependencies

High dependency on the BSE for regulatory approvals regarding share capital and on global app stores (Android/iOS) for product distribution.

Technology Obsolescence Risk

High risk; success depends on staying current with technology trends to retain skilled professionals and provide competitive BPO/development services.